XTX Topco Ltd Acquires 15,997 Shares of Catalent, Inc. (NYSE:CTLT)

XTX Topco Ltd raised its holdings in shares of Catalent, Inc. (NYSE:CTLT) by 191.6% during the second quarter, according to its most recent filing with the SEC. The firm owned 24,348 shares of the company’s stock after purchasing an additional 15,997 shares during the period. XTX Topco Ltd’s holdings in Catalent were worth $1,369,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the business. Norges Bank purchased a new stake in shares of Catalent during the 4th quarter worth $116,021,000. Capital World Investors raised its holdings in Catalent by 6.1% in the fourth quarter. Capital World Investors now owns 19,079,994 shares of the company’s stock worth $857,264,000 after purchasing an additional 1,098,474 shares in the last quarter. Magnetar Financial LLC purchased a new stake in shares of Catalent during the first quarter valued at about $56,429,000. Cadian Capital Management LP boosted its holdings in shares of Catalent by 14.3% in the 4th quarter. Cadian Capital Management LP now owns 6,064,384 shares of the company’s stock valued at $272,473,000 after buying an additional 759,600 shares in the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its position in shares of Catalent by 2,792.9% in the 1st quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 516,390 shares of the company’s stock worth $29,150,000 after buying an additional 498,540 shares during the last quarter.

Catalent Stock Performance

Shares of CTLT opened at $60.00 on Friday. The company has a debt-to-equity ratio of 1.35, a quick ratio of 1.77 and a current ratio of 2.52. The stock has a 50-day moving average of $59.48 and a two-hundred day moving average of $57.21. The stock has a market cap of $10.86 billion, a P/E ratio of -9.84, a P/E/G ratio of 1.88 and a beta of 1.15. Catalent, Inc. has a one year low of $31.80 and a one year high of $61.20.

Analyst Ratings Changes

A number of research firms recently commented on CTLT. William Blair reissued a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. StockNews.com began coverage on Catalent in a research report on Wednesday. They issued a “sell” rating for the company. Barclays upped their target price on Catalent from $47.00 to $63.00 and gave the company an “equal weight” rating in a research report on Friday, June 28th. Finally, Royal Bank of Canada reissued a “sector perform” rating and issued a $63.50 price target on shares of Catalent in a report on Thursday, July 11th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $58.08.

Insider Transactions at Catalent

In other Catalent news, CEO Alessandro Maselli sold 9,088 shares of Catalent stock in a transaction that occurred on Monday, July 29th. The shares were sold at an average price of $58.76, for a total transaction of $534,010.88. Following the completion of the sale, the chief executive officer now directly owns 177,521 shares in the company, valued at approximately $10,431,133.96. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, CFO Matti Masanovich sold 2,993 shares of the firm’s stock in a transaction dated Monday, July 8th. The stock was sold at an average price of $56.74, for a total transaction of $169,822.82. Following the sale, the chief financial officer now directly owns 33,871 shares of the company’s stock, valued at $1,921,840.54. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Alessandro Maselli sold 9,088 shares of the business’s stock in a transaction that occurred on Monday, July 29th. The shares were sold at an average price of $58.76, for a total value of $534,010.88. Following the completion of the transaction, the chief executive officer now directly owns 177,521 shares of the company’s stock, valued at $10,431,133.96. The disclosure for this sale can be found here. Insiders sold a total of 13,409 shares of company stock worth $782,923 over the last three months. 0.31% of the stock is currently owned by insiders.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.